Although wild-type PD-L1-Fc has shown therapeutic potential in autoimmune models such as colitis and arthritis, whether Fc-engineered, ADCC-silent PD-L1-Fc can modulate the unique immune microenvironment at the maternal–fetal interface remains unknown. This evidence concerns the gene CD274 and colitis.